Rigel Pharmaceuticals Inc (NAS:RIGL)
$ 16.5 -0.76 (-4.4%) Market Cap: 304.04 Mil Enterprise Value: 303.15 Mil PE Ratio: 75.04 PB Ratio: 0 GF Score: 77/100

Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 03:30PM GMT
Release Date Price: $29.9 (+9.93%)
Tessa Thomas Romero
JP Morgan Chase & Co, Research Division - Associate

Welcome, everyone, to the Thursday morning of the 2020 JPMorgan Health Care Conference. My name is Tessa Romero, and I'm one of the biotechnology analysts here at JPMorgan. On behalf of myself and the team, I'm pleased to welcome to the stage Rigel Pharmaceuticals. And presenting on behalf of the company is CEO, Raul Rodriguez. Raul?

Raul R. Rodriguez
Rigel Pharmaceuticals, Inc. - President, CEO & Director

Thank you, Tessa, and good morning. Thank you for joining us. Thank you for -- to you and your colleagues at JPMorgan for inviting us again. It's a pleasure to be here and kick off the year in good fashion.

So let me introduce Rigel to you. Some of you don't know us. I'll tell you a little bit more of the story for those of you who do know us. Some important forward-looking statements, you could read these on our website as well. Let me go to the story.

There are 4 main key value drivers for Rigel, and as you see on this slide. And I'll take you through each

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot